In patients with a prior CV event who needed more additional lipid-lowering, the 75 mg Praluent® dose was used 78% of the time in the ODYSSEY OUTCOMES study1
Customised treatment with Praluent®
Dosage information2
The dose of Praluent® can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). If additional LDL-C reduction is needed in patients treated with 75 mg Q2W or 300 mg once Q4W (monthly), the dosage may be adjusted to the maximum dosage of 150 mg Q2W.
If a dose is missed, the patient should administer the injection as soon as possible and thereafter resume treatment on the original schedule.
PRALUENT INDICATION
Learn more
HOW TO INJECT PRALUENT
Learn more
CV=cardiovascular; LDL-C=low-density lipoprotein cholesterol; Q2W=once every two weeks; Q4W=once every four weeks.
- Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/medicine/30956. Accessed October 2020.
- Praluent® (alirocumab) European Summary of Product Characteristics. March 2019.